Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), consisting of the full 44-amino acid sequence of endogenous GHRH modified with a trans-3-hexenoic acid group. Specifically, this chemical addition stabilizes the peptide against rapid enzymatic degradation, significantly extending its biological activity. tesamorelin peptide

In contrast to direct growth hormone administration, Tesamorelin acts upstream to stimulate the pituitary gland in a physiologically pulsatile manner. Mechanistically, this pulsatile secretion preserves the natural negative feedback mechanisms of the hypothalamic-pituitary-somatotropic axis, avoiding complete axis suppression. tesamorelin peptide

Consequently, clinical and preclinical research into Tesamorelin has primarily focused on its capacity to reduce visceral adiposity—the hazardous accumulation of deep abdominal fat associated with metabolic and cardiovascular risk. In addition, studies demonstrate its ability to selectively mobilize visceral fat while exerting a relatively neutral effect on subcutaneous fat and insulin sensitivity. Furthermore, researchers have documented favorable secondary effects on lipid profiles and lean body mass in populations affected by metabolic dysregulation. Overall, Tesamorelin serves as an essential research tool for evaluating pituitary GH secretion dynamics and the systemic metabolic effects of targeted GH axis stimulation.